{
  "id": 10011796,
  "title": "FDA approves AbbVie next-gen dopamine therapy for Parkinson's",
  "url": "https://urgent.news/2026/09/26/fda-approves-abbvie-next-gen-dopamine-therapy-for-parkinsons",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-26T16:01:44.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/fda-approves-abbvie-next-gen-dopamine-therapy-for-parkinsons/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The US Food and Drug Administration has approved AbbVie's treatment for Parkinson's disease in adults. The drug, tavapadon, will be sold under the brand name Juvmo and comes as a once-a-day pill. According to AbbVie, more than 11 million people live with Parkinson's disease worldwide.\n\nJuvmo works by mimicking dopamine, a vital brain chemical that naturally decreases in people with Parkinson's. The FDA's approval was based on data from AbbVie's late-stage trial program, which showed the drug improved symptoms in patients with the disease. Common side effects reported in the trials included nausea, dizziness, and headache.\n\nAbbVie gained access to tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics in 2023. Citi analysts had previously said the launch was expected in the third quarter of 2026, with AbbVie targeting more than $5 billion in combined Parkinson's disease sales.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Hindu Health",
        "title": "U.S. FDA approves AbbVie's drug for Parkinson's disease",
        "url": "https://urgent.news/2026/09/26/u-s-fda-approves-abbvies-drug-for-parkinsons-disease",
        "published": "2026-09-26T05:47:52.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}